{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:39:52Z","timestamp":1790177992141,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T00:00:00Z","timestamp":1528156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Discoid lupus erythematosus (<jats:styled-content style=\"fixed-case\">DLE<\/jats:styled-content>) and dermatomyositis (<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>) are inflammatory autoimmune diseases that manifest primarily in the skin but can be linked to systemic complications. Although there is an in\u2010depth understanding of the clinical presentation of these two diseases, much less is known regarding the pathophysiology. This has limited the effective treatment options for patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>An understanding of the pathogenesis of each disease in greater detail will lead to newer targeted medications with less morbidity. This review article endeavors to substantiate the use of new treatments which target the <jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">STAT<\/jats:styled-content> pathway while elaborating on the immunopathology as well.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed was searched for relevant review articles, case reports, case series reports, randomized clinical trials (<jats:styled-content style=\"fixed-case\">RCT<\/jats:styled-content>s), basic science articles. Appropriate key terms and Me<jats:styled-content style=\"fixed-case\">SH<\/jats:styled-content> terms were utilized in the search. Clinicaltrials.gov was used to find relevant and current clinical trials being conducted in <jats:styled-content style=\"fixed-case\">DLE<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content> patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A review of the literature supports the proposal that though there are likely many components and pathways involved in the destruction of keratinocytes, the Th1 cell immune response and specifically the <jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">STAT<\/jats:styled-content> signaling pathway is common to both <jats:styled-content style=\"fixed-case\">DLE<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although further study is needed to determine the efficacy and benefits of <jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content> inhibitors over conventional therapy, these medications should be considered in refractory cases.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.14064","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T01:44:09Z","timestamp":1528249449000},"page":"1007-1014","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["<scp>JAK<\/scp>\u2010<scp>STAT<\/scp> signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis"],"prefix":"10.1111","volume":"57","author":[{"given":"Jared S.","family":"Kahn","sequence":"first","affiliation":[{"name":"Tufts University School of Medicine Boston MA USA"},{"name":"Department of Dermatology Tufts Medical Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya Chowdary","family":"Deverapalli","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tufts Medical Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Rosmarin","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine Boston MA USA"},{"name":"Department of Dermatology Tufts Medical Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.21"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14539"},{"key":"e_1_2_9_4_1","first-page":"1689","volume-title":"Dermatology","author":"Bolognia JL","year":"2012"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2017.02.013"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2009.02.080075"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.008"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.100486"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120621"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8652-1"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2014.11.026"},{"key":"e_1_2_9_12_1","first-page":"1417","article-title":"Autoantibodies as predictors of disease","volume":"108","author":"Leslie D","year":"2001","journal-title":"Infect Immun"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.67.1.227"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033753"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10825.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2009.06.013"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10479.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0706-2"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10301.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7074829"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.269"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24449"},{"key":"e_1_2_9_23_1","unstructured":"CompanyEL.A study of baricitinib (LY3009104) in participants with systemic lupus erythematosus (SLE). Clinicaltrials.gov. 2016."},{"key":"e_1_2_9_24_1","unstructured":"RosmarinD.Open label phase 2 pilot trial of oral tofactinib in adult subjects with discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE). Boston MA; 2017. Report No.: NCT03159936."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052023"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3531"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22558"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2009.24.4.715"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052454"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2010.02.014"},{"key":"e_1_2_9_31_1","first-page":"668","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis","volume":"167","author":"Kurtzman DJB","year":"2016","journal-title":"JAMA Dermatol"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1412997"},{"key":"e_1_2_9_33_1","unstructured":"Clinicaltrials.gov. Study of tofacitinib in refractory dermatomyositis [Internet]. Baltimore MD; 2017. Report No.: NCT03002649. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03002649?term=NCT03002649&rank=1"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177057"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.02.015"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39818"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.107"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.08.009"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijd.14064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.14064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T16:45:19Z","timestamp":1694969119000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.14064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,5]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1111\/ijd.14064"],"URL":"https:\/\/doi.org\/10.1111\/ijd.14064","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,5]]},"assertion":[{"value":"2017-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}